Specialty Pharmacy

The process of adding biosimilars to formularies will be much more rigorous than what the industry is accustomed to seeing in the generic molecule space, asserted Steven Lucio, senior director, Clinical Solutions and Pharmacy Program Development at Novation.

The FDA approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.

We will see a new wave of oral antiviral hepatitis C medicines hitting the market towards the end of this year and the beginning of next year, noted Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts.

Specialty Pharmacy Times spoke to Peter Wickersham, senior vice president, cost of care at Prime Therapeutics, to help us highlight the key points of the 2013 Specialty Drug Trend Insights report and its implications for the future of specialty spending.

Chronic myeloid leukemia patients likely have comorbid conditions at the time of their diagnosis; however, most tyrosine-kinase inhibitor studies exclude patients with these conditions.

The changing health care environment and the integration of specialty pharmacies into health systems were the biggest themes during one of the liveliest panels at the Therigy conference last month in Orlando, Florida.

Steven Lucio of Novation discusses why now is the time for pharmacists to educate themselves about biosimilars and the complexities surrounding biologic manufacturing.

Cultivating a career in specialty pharmacy has never been more exciting.

Data presented by Gary Rice of Diplomat Specialty Pharmacy at the 2013 Academy of Managed Care Pharmacy Nexus meeting suggest that partial-fill strategies for specialty pharmaceuticals produce a sizable decrease in total spend.

In a session at the 2013 Academy of Managed Care Pharmacy Nexus meeting, Aimee Tharaldson, PharmD, identified the top specialty drugs in the pipeline and highlighted the most recent therapeutic trends within the inflammatory conditions class.

Formal oncology clinical practice guidelines are not as reliable as some may think, suggests a study presented at the 2013 Academy of Managed Care Pharmacy Nexus meeting.

During AMCP Nexus, we spoke to Beckie Fenrick, pharmacy practice leader at Stoney Hill Partners and Cambridge Advisory Group, about 340B, copay cards, integrating the pharmacy and medical benefits, and potential problems regarding site-of-service optimization. Listen to the audio now!

Leigh Ann Bruhn, director of Avalere Health, notes that limited distribution for specialty pharmaceuticals can improve a manufacturer's data capture capabilities.

Value Specialty Pharmacy announced that effective November 1, 2013, it has been awarded a Full Specialty Pharmacy Accreditation from URAC.

For biopharmaceutical firms developing treatments for rare diseases, economic incentives are rarely the only reason to begin developing orphan drugs.

A good response to tumor necrosis factor inhibitors taken to treat rheumatoid arthritis comes along with the added benefit of reduced risk of acute coronary syndrome, a study finds.

The Specialty Pharmacy Association of America (SPAARx) recently announced that Gaston Bernstein, president & CEO of Biomed Pharmaceuticals, and Nuaman Tyyeb, president/managing partner of CareMed Pharmaceutical Services, Inc, will join the SPAARx Board of Directors.

Edmund Pezalla, MD, MPH, national medical director, pharmacy policy and strategy at Aetna, explains how drugs that have been deemed "failures" can sometimes become effective treatments for other conditions.

Specialty Pharmacy Times is proud to announce the launch of the inaugural Specialty Pharmacy Times Industry Guide, a comprehensive directory of organizations, products, and services that will serve as a one-stop guide for industry stakeholders in the specialty pharmacy space.

As the popularity of copay cards for expensive specialty medications increases, health plans are devising new ways to steer patients into using more cost-effective options.

The FDA has asked the manufacturer of the leukemia chemotherapy drug Iclusig (ponatinib) to suspend marketing and sales of Iclusig because of the risk of life-threatening blood clots and severe narrowing of blood vessels.

Results of a phase-2b trial reveal preliminary information about the efficacy of the combination treatment of faldaprevir and deleobuvir for hepatitis C virus infection.

In this video, Todd Speranzo of Avella talks about how to create video content that is compelling to patients.

HIV positive patients who become distressed more easily may be less likely to adhere to antiretroviral treatment (ART), suggest the results of a study appearing in the September 2013 edition of Behavior Therapy.

To improve the care of patients with hemophilia and von Willebrand's Disease (vWD), coagulation factor products should be billed through the pharmacy benefit and provided by specialty pharmacies, the authors of a new study suggest.

In this video from the 2013 Armada Specialty Pharmacy Summit, Mark Zitter of Zitter Health Insights discusses stakeholder views on copay cards.

Interstitial lung disease (ILD) is a known rare side effect of interferon treatment. Investigators confirmed the low incidence if ILD in patients with hepatitis C receiving interferon, but also recorded reductions in lung function in almost half of treated patients.